Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized @:@ to pemetrexed and carboplatin ( or cisplatin ) or ramucirumab ( @ mg/kg ) plus pemetrexed and carboplatin ( or cisplatin ) once every @ weeks .